U.S. markets closed
  • S&P Futures

    3,941.00
    -30.75 (-0.77%)
     
  • Dow Futures

    31,715.00
    -124.00 (-0.39%)
     
  • Nasdaq Futures

    11,871.75
    -163.50 (-1.36%)
     
  • Russell 2000 Futures

    1,782.90
    -8.90 (-0.50%)
     
  • Crude Oil

    109.56
    -0.73 (-0.66%)
     
  • Gold

    1,848.90
    +1.10 (+0.06%)
     
  • Silver

    21.89
    +0.16 (+0.75%)
     
  • EUR/USD

    1.0668
    -0.0029 (-0.27%)
     
  • 10-Yr Bond

    2.8590
    +0.0720 (+2.58%)
     
  • Vix

    28.48
    -0.95 (-3.23%)
     
  • GBP/USD

    1.2550
    -0.0038 (-0.30%)
     
  • USD/JPY

    127.9100
    +0.0220 (+0.02%)
     
  • BTC-USD

    29,197.21
    -903.46 (-3.00%)
     
  • CMC Crypto 200

    654.46
    -20.41 (-3.02%)
     
  • FTSE 100

    7,513.44
    +123.46 (+1.67%)
     
  • Nikkei 225

    26,907.64
    -93.88 (-0.35%)
     

Savara to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

AUSTIN, Texas, January 04, 2022--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the H.C. Wainwright BIOCONNECT Virtual Conference being held January 10-13, 2022. A webcast of the presentation will be available at 7:00 AM ET/4:00 AM PT on January 10, 2022 on Savara’s website at www.savarapharma.com/investors/events-presentations/ and archived for 90 days.

About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).

View source version on businesswire.com: https://www.businesswire.com/news/home/20220104005183/en/

Contacts

Savara Inc. IR & PR
Anne Erickson
Senior Vice President, Chief of Staff
anne.erickson@savarapharma.com
(512) 851-1366